Skip to main content


Small organisms, big impact

We’re looking for passionate, smart, and dynamic individuals to join us as we ignite a revolution in the treatment of disease.

Our team at Seres Therapeutics represents an array of backgrounds and interests with one important thing in common: a singular mission to transform the lives of patients by targeting the underlying cause of their diseases.

We welcome new team members with diverse interests, relentless curiosity, and scientific prowess to help us establish a new treatment paradigm.

A world-changing vision

Seres is a FierceBiotech “Fierce 15,” company and is led by some of biopharma’s best and brightest. Seres’ lead therapeutic candidate, SER-109 for the treatment of recurrent Clostridium difficile infection, is currently in Phase 3 development. SER-109 had been designated by the FDA as a Breakthrough Therapy and it has obtained orphan drug designation.

We’re located in the heart of the biotech industry, in Cambridge, MA, a booming district just across the Charles River from the city of Boston with proximity to some of the world’s best hospitals and academic research institutions.

Our team members are excited by the opportunity to get in at the ground floor of an exciting company. They’ve brought their expertise and are helping to build, grow, and shape Seres for the future.

Interested in learning more? Our current openings are listed below.

Even if you don’t see a job that’s a fit, but you’re excited by what Seres is doing and want to be a part of it, we’d appreciate hearing from you and will keep you in mind for a future opportunity. Click here to submit your resume.

Filter Jobs:

Department Position Title City State
Regulatory Executive Director, Regulatory Affairs Cambridge MA
QA Principal Associate, Quality Assurance - Contract Cambridge MA
QA Senior Associate, QA Training - Contractor Cambridge MA
Regulatory Senior Manager, Regulatory Affairs Cambridge MA
Manufacturing Sr. Validation Engineer Cambridge MA

Our Phase 3 Lead Candidate SER-109

Learn more about SER-109, our Phase 3 lead development candidate


Clinical Trials

Review our ongoing clinical trials


Back to top